Advising patients seeking stem cell interventions for multiple sclerosis.

Practical Neurology
Beatrice von WunsterClaire M Rice

Abstract

Given the intuitive potential of stem cell therapy and limitations of current treatment options for progressive multiple sclerosis (MS), it is not surprising that patients consider undertaking significant clinical and financial risks to access stem cell transplantation. However, while increasing evidence supports autologous haematopoietic stem cell transplantation (AHSCT) in aggressive relapsing-remitting MS, interventions employing haematopoietic or other stem cells should otherwise be considered experimental and recommended only in the context of a properly regulated clinical study. Understandably, most neurologists are unfamiliar with AHSCT procedures and the specific requirements for quality assurance and safety standards, as well as post-procedure precautions and follow-up. Consequently they may feel ill-equipped to advise patients. Here, we highlight important points for discussion in consultations with patients considering stem cell 'tourism' for MS.

References

Aug 10, 2000·Nature·R McKay
Mar 15, 2005·Bone Marrow Transplantation·A GratwohlUNKNOWN Autoimmune Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Feb 1, 2007·Multiple Sclerosis : Clinical and Laboratory Research·R SaccardiUNKNOWN Autoimmune Diseases Working Party of EBMT
Oct 31, 2008·Lancet·Alastair Compston, Alasdair Coles
Jun 19, 2012·Cell Stem Cell·George Q Daley
Sep 13, 2012·Critical Care : the Official Journal of the Critical Care Forum·Pashtoon M KasiHrishikesh S Kulkarni
Nov 30, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Harold L Atkins, Mark S Freedman
May 16, 2013·Blood·Karen K BallenHal E Broxmeyer
Sep 10, 2015·The New England Journal of Medicine·Hermes Taylor-Weiner, Joshua Graff Zivin
Jan 17, 2016·Stem Cell Research & Therapy·Maha M BakhuraysahSteven Petratos
Apr 14, 2016·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Daniela Currò, Gianluigi Mancardi
Dec 14, 2016·The New England Journal of Medicine·Peter W MarksRobert M Califf
Apr 30, 2017·Neurology·Maria Pia SormaniGian Luigi Mancardi
May 27, 2017·Multiple Sclerosis : Clinical and Laboratory Research·Juliana RedondoClaire M Rice
Jul 7, 2017·Science Translational Medicine·Douglas SippJohn E J Rasko
Oct 21, 2017·Brain : a Journal of Neurology·Neil J ScoldingUNKNOWN International Conference on Cell-Based Therapies for Multiple Sclerosis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Neurología : publicación oficial de la Sociedad Española de Neurología
A SaizF Graus
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
G L Mancardi
© 2022 Meta ULC. All rights reserved